Targeting of CD38 has been posited as a potential therapeutic avenue for the treatment of immune-mediated conditions. A phase 2 study now reports promising safety, tolerability and intermediate endpoint of efficacy outcomes with the anti-CD38 monoclonal antibody felzartamab in kidney transplant recipients with antibody-mediated rejection.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Camponeschi, A. et al. Human CD38 regulates B cell antigen receptor dynamic organization in normal and malignant B cells. J. Exp. Med. 219, e20220201 (2022).
Mayer, K. A. et al. A randomized phase 2 trial of felzartamab in antibody-mediated rejection. N. Engl. J. Med. 391, 122–132 (2024).
Hogan, K. A., Chini, C. C. S. & Chini, E. N. The multi-faceted ecto-enzyme CD38: roles in immunomodulation, cancer, aging, and metabolic diseases. Front. Immunol. 10, 1187 (2019).
Zeidler, J. D. et al. The CD38 glycohydrolase and the NAD sink: implications for pathological conditions. Am. J. Physiol. Cell Physiol. 322, C521–C545 (2022).
Boslett, J., Helal, M., Chini, E. & Zweier, J. L. Genetic deletion of CD38 confers post-ischemic myocardial protection through preserved pyridine nucleotides. J. Mol. Cell. Cardiol. 118, 81–94 (2018).
van de Donk, N. W. et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol. Rev. 270, 95–112 (2016).
Langer, P. et al. Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant. Cochrane Database Syst. Rev. 5, CD013595 (2024).
Loupy, A. & Lefaucheur, C. Antibody-mediated rejection of solid-organ allografts. N. Engl. J. Med. 379, 1150–1160 (2018).
Lamarthée, B. et al. Transcriptional and spatial profiling of the kidney allograft unravels a central role for FcyRIII+ innate immune cells in rejection. Nat. Commun. 14, 4359 (2023).
Floege, J. et al. Felzartamab (anti-CD38) in patients with IgA nephropathy — interim results from the IGNAZ study. Nephrol. Dial. Transplant. 39 (Suppl. 1), 425 (2024).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Rabelink, T.J., de Vries, A.P.J. CD38 — a new target in renal immune disease. Nat Rev Nephrol 20, 641–642 (2024). https://doi.org/10.1038/s41581-024-00874-6
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41581-024-00874-6
